» Articles » PMID: 1234486

Plasma Levels and Beta-adrenoceptor Blockade with Acebutolol, Practolol and Propranolol in Man

Overview
Specialty Pharmacology
Date 1975 Feb 1
PMID 1234486
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

1 The degree of beta-adrenoceptor blockade of isoprenaline-induced tachycardia has been determined in three healthy volunteers after the administration of single oral doses of acebutolol, practolol or propranolol. 2 Plasma levels of these drugs were determined either colorimetrically (acebutolol and practolol) or fluorimetrically (propranolol). The colorimetric assay of acebutolol in plasma is fully described but the other drugs were assayed by published methods. 3 The degree of beta-adrenoceptor blockade and the plasma level for acebutolol and practolol were well correlated, whereas in the case of propranolol correlation was poor, due in part to the presence in plasma of active metabolites not detected by the fluorimetric assay. The plasma levels of practolol and propranolol are in agreement with those previously reported. 4 The maximum cardiac beta-adrenoceptor blockade achieved in this study with the respective single oral doses of acebutolol (300 mg), practolol (400 mg) or propranolol (40 mg) were similar in each of the three subjects. Therefore the beta-adrenoceptor blocking potencies of these drugs against isoprenaline-induced tachycardia are inversely related to these doses; indicating that propranolol is 7-8 times more potent than acebutolol and the latter slightly more potent than practolol.

Citing Articles

A standard approach to compiling clinical pharmacokinetic data.

Sheiner L, Benet L, Pagliaro L J Pharmacokinet Biopharm. 1981; 9(1):59-127.

PMID: 7014827 DOI: 10.1007/BF01059343.


Comparison of once and twice daily administration of acebutolol in hypertension.

Watson R, Stallard T, Littler W Br J Clin Pharmacol. 1980; 9(2):209-12.

PMID: 6766731 PMC: 1429867. DOI: 10.1111/j.1365-2125.1980.tb05835.x.


Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol.

Gribbin H, Mackay A, Baldwin C, Tattersfield A Br J Clin Pharmacol. 1981; 12(1):61-5.

PMID: 6264936 PMC: 1401756. DOI: 10.1111/j.1365-2125.1981.tb01855.x.


Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Singh B, Thoden W, Ward A Drugs. 1985; 29(6):531-69.

PMID: 3891306 DOI: 10.2165/00003495-198529060-00003.


The effect of propranolol on exercise induced tachycardia is determined by plasma concentration and the density of adrenergic receptors on leukocytes.

Tawara K, Steiner E, von Bahr C Eur J Clin Pharmacol. 1987; 31(6):667-72.

PMID: 3830254 DOI: 10.1007/BF00541293.


References
1.
Traub Y, Shaver J, MCDONALD Jr R, Shapiro A . Effects of practolol on pressor responses to noxious stimuli in hypertensive patients. Clin Pharmacol Ther. 1973; 14(2):165-74. DOI: 10.1002/cpt1973142165. View

2.
Basil B, Collins R, Cuthbert M . Pharmacokinetics of M&B 17,803A in animals and man. Br J Pharmacol. 1973; 47(3):620P. PMC: 1776296. View

3.
Basil B, Jordan R, Loveless A, Maxwell D . Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol. 1973; 48(2):198-211. PMC: 1776183. DOI: 10.1111/j.1476-5381.1973.tb06906.x. View

4.
Coltart D, SHAND D . Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J. 1970; 3(5725):731-4. PMC: 1701661. DOI: 10.1136/bmj.3.5725.731. View

5.
Fitzgerald J, ODonnell S . Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol. 1971; 43(1):222-35. PMC: 1665931. DOI: 10.1111/j.1476-5381.1971.tb07171.x. View